Overview
Sironax is a clinical-stage biotechnology company founded in 2017 that develops small-molecule therapeutics targeting fundamental mechanisms of aging and age-related degeneration. The company's pipeline focuses on modulating dysregulated cellular death pathways, energy homeostasis, and inflammatory signaling through inhibitors of SARM1, RIPK1, and activators of NAMPT, with applications in neurodegenerative, metabolic, and inflammatory diseases. Sironax operates globally with offices in the United States, China, Switzerland, and Australia, and has established a proprietary Brain Delivery Module platform for enhanced blood-brain barrier penetration of therapeutic payloads.